Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24796119 | 0.87 | KDM4E (0.48) | KMT2AKDM4ETSHRHTTMAPK1 | |
| SCHEMBL21389251 | 0.84 | HTT (0.54) | KMT2ATSHRHTT | |
| SCHEMBL21389186 | 0.84 | KDM4E (0.49) | KMT2AKDM4ETSHRMAPK1RAB9A | |
| SCHEMBL21389461 | 0.84 | KMT2A (0.43) | KMT2AKDM4ETSHRHTTMAPK1 | |
| SCHEMBL7328278 | 0.82 | KMT2A (0.50) | KMT2AKDM4ETSHRHTTMAPK1 | |
| SCHEMBL24796621 | 0.81 | KMT2A (0.55) | KMT2AKDM4ETSHRHTTMAPK1 | |
| SCHEMBL14828748 | 0.80 | KMT2A (0.53) | KMT2AKDM4ETSHRHTTMAPK1 | |
| SCHEMBL24795970 | 0.80 | POLB (0.41) | KMT2AKDM4ETSHRMAPK1POLB | |
| SCHEMBL9206004 | 0.80 | HTT (0.59) | KMT2ATSHRHTTMAPK1POLB | |
| SCHEMBL21389288 | 0.79 | KMT2A (0.44) | KMT2AKDM4ETSHRHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2019183577-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | KMT2A 3040/4885KDM4E 3433/4885TSHR 140/4885 |
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | KMT2A 2741/4885KDM4E 3179/4885TSHR 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.